Eduardo Reátegui
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eduardo Reátegui.
Advanced Materials | 2015
Eduardo Reátegui; Nicola Aceto; Eugene J. Lim; James P. Sullivan; Anne E. Jensen; Mahnaz Zeinali; Joseph M. Martel; A. J. Aranyosi; Wei Li; Steven A. Castleberry; Aditya Bardia; Lecia V. Sequist; Daniel A. Haber; Shyamala Maheswaran; Paula T. Hammond; Mehmet Toner; Shannon L. Stott
A layer-by-layer gelatin nanocoating is presented for use as a tunable, dual response biomaterial for the capture and release of circulating tumor cells (CTCs) from cancer patient blood. The entire nanocoating can be dissolved from the surface of microfluidic devices through biologically compatible temperature shifts. Alternatively, individual CTCs can be released through locally applied mechanical stress.
Biomaterials | 2015
Wei Li; Eduardo Reátegui; Myoung-Hwan Park; Steven A. Castleberry; Jason Z. Deng; Bryan B. Hsu; Sarah Mayner; Anne E. Jensen; Lecia V. Sequist; Shyamala Maheswaran; Daniel A. Haber; Mehmet Toner; Shannon L. Stott; Paula T. Hammond
Selective isolation and purification of circulating tumor cells (CTCs) from whole blood is an important capability for both clinical medicine and biological research. Current techniques to perform this task place the isolated cells under excessive stresses that reduce cell viability, and potentially induce phenotype change, therefore losing valuable information about the isolated cells. We present a biodegradable nano-film coating on the surface of a microfluidic chip, which can be used to effectively capture as well as non-invasively release cancer cell lines such as PC-3, LNCaP, DU 145, H1650 and H1975. We have applied layer-by-layer (LbL) assembly to create a library of ultrathin coatings using a broad range of materials through complementary interactions. By developing an LbL nano-film coating with an affinity-based cell-capture surface that is capable of selectively isolating cancer cells from whole blood, and that can be rapidly degraded on command, we are able to gently isolate cancer cells and recover them without compromising cell viability or proliferative potential. Our approach has the capability to overcome practical hurdles and provide viable cancer cells for downstream analyses, such as live cell imaging, single cell genomics, and inxa0vitro cell culture of recovered cells. Furthermore, CTCs from cancer patients were also captured, identified, and successfully released using the LbL-modified microchips.
Journal of the American Chemical Society | 2017
Myoung-Hwan Park; Eduardo Reátegui; Wei Li; Shannon N. Tessier; Keith H. K. Wong; Anne E. Jensen; Vishal Thapar; David T. Ting; Mehmet Toner; Shannon L. Stott; Paula T. Hammond
The detection of rare circulating tumor cells (CTCs) in the blood of cancer patients has the potential to be a powerful and noninvasive method for examining metastasis, evaluating prognosis, assessing tumor sensitivity to drugs, and monitoring therapeutic outcomes. In this study, we have developed an efficient strategy to isolate CTCs from the blood of breast cancer patients using a microfluidic immune-affinity approach. Additionally, to gain further access to these rare cells for downstream characterization, our strategy allows for easy detachment of the captured CTCs from the substrate without compromising cell viability or the ability to employ next generation RNA sequencing for the identification of specific breast cancer genes. To achieve this, a chemical ligand-exchange reaction was engineered to release cells attached to a gold nanoparticle coating bound to the surface of a herringbone microfluidic chip (NP-HBCTC-Chip). Compared to the use of the unmodified HBCTC-Chip, our approach provides several advantages, including enhanced capture efficiency and recovery of isolated CTCs.
Nature Biomedical Engineering | 2017
Eduardo Reátegui; Fatemeh Jalali; Aimal H. Khankhel; Elisabeth Wong; Hansang Cho; Jarone Lee; Charles N. Serhan; Jesmond Dalli; Hunter Elliott; Daniel Irimia
Neutrophil swarms protect healthy tissues by sealing off sites of infection. In the absence of swarming, microbial invasion of surrounding tissues can result in severe infections. Recent observations in animal models have shown that swarming requires rapid neutrophil responses and well-choreographed neutrophil migration patterns. However, in animal models physical access to the molecular signals coordinating neutrophil activities during swarming is limited. Here, we report the development and validation of large microscale arrays of zymosan-particle clusters for the study of human neutrophils during swarming ex vivo. We characterized the synchronized swarming of human neutrophils under the guidance of neutrophil-released chemokines, and measured the mediators released at different phases of human-neutrophil swarming against targets simulating infections. We found that the network of mediators coordinating human-neutrophil swarming includes start and stop signals, proteolytic enzymes and enzyme inhibitors, as well as modulators of activation of other immune and non-immune cells. We also show that the swarming behavior of neutrophils from patients following major trauma is deficient and gives rise to smaller swarms than those of neutrophils from healthy individuals.
Nature Communications | 2018
Eduardo Reátegui; Kristan E. van der Vos; Charles P. Lai; Mahnaz Zeinali; Nadia A. Atai; Berent Aldikacti; Frederick P. Floyd; Aimal H. Khankhel; Vishal Thapar; Fred H. Hochberg; Lecia V. Sequist; Brian V. Nahed; Bob S. Carter; Mehmet Toner; Leonora Balaj; David T. Ting; Xandra O. Breakefield; Shannon L. Stott
Extracellular vesicles (EVs) carry RNA, DNA, proteins, and lipids. Specifically, tumor-derived EVs have the potential to be utilized as disease-specific biomarkers. However, a lack of methods to isolate tumor-specific EVs has limited their use in clinical settings. Here we report a sensitive analytical microfluidic platform (EVHB-Chip) that enables tumor-specific EV-RNA isolation within 3u2009h. Using the EVHB-Chip, we achieve 94% tumor-EV specificity, a limit of detection of 100 EVs per μL, and a 10-fold increase in tumor RNA enrichment in comparison to other methods. Our approach allows for the subsequent release of captured tumor EVs, enabling downstream characterization and functional studies. Processing serum and plasma samples from glioblastoma multiforme (GBM) patients, we can detect the mutant EGFRvIII mRNA. Moreover, using next-generation RNA sequencing, we identify genes specific to GBM as well as transcripts that are hallmarks for the four genetic subtypes of the disease.Extracellular vesicles can carry many different types of biological cargo and have been investigated as a biomarker for cancer diagnosis. Here the authors develop a microfluidic platform for rapid and sensitive isolation of tumor-specific extracellular vesicles.
Lab on a Chip | 2017
Xiaocheng Jiang; Keith H. K. Wong; Aimal H. Khankhel; Mahnaz Zeinali; Eduardo Reátegui; Matthew J. Phillips; Xi Luo; Nicola Aceto; Fabio Fachin; Anh Hoang; Wooseok Kim; Annie E. Jensen; Lecia V. Sequist; Shyamala Maheswaran; Daniel A. Haber; Shannon L. Stott; Mehmet Toner
Lab on a Chip | 2018
Jae Jung Kim; Eduardo Reátegui; Alex Hopke; Fatemeh Jalali; Maedeh Roushan; Patrick S. Doyle; Daniel Irimia
PMC | 2016
Ki Wan Bong; Eduardo Reátegui; Daniel Irimia; Jae Jung Kim; Patrick S. Doyle
PMC | 2015
Eduardo Reátegui; Bryan Hsu; Anne E. Jensen; Lecia V. Sequist; Shyamala Maheswaran; Daniel A. Haber; Mehmet Toner; Shannon L. Stott; Wei Li; Myoung Hwan Park; Steven A. Castleberry; Zhou Deng; Bryan B. Hsu; Sarah Mayner; Paula T. Hammond
Archive | 2015
Mehmet Toner; Shannon L. Stott; Eduardo Reátegui; Xiaoncheng Jiang